NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT06034275,Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies,https://clinicaltrials.gov/study/NCT06034275,,RECRUITING,"Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies",NO,Acute Myeloid Leukemia|B-cell Acute Lymphoblastic Leukemia|High-risk Myelodysplastic Syndrome,DRUG: VIP943 (QW)|DRUG: VIP943 (BIW),"Incidence of DLT (Dose limit toxicity) of VIP943, Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 28 days","Response rate to VIP943 as assessed by investigators using disease-specific response criteria, Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 28 days (up to approximately 10 months)|Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of VIP943, Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 28 days|Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of VIP943, Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 28 days",,"Vincerx Pharma, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,VNC-943-101,2023-09-13,2025-05-30,2025-12-31,2023-09-13,,2024-11-15,"University of Alabama at Birmingham, Birmingham, Alabama, 35233, United States|University of Cincinnati, Cincinnati, Ohio, 45219, United States|TriStar Bone Marrow Transplant, Nashville, Tennessee, 37203, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Fred Hutchinson Cancer Center, Seattle, Washington, 98109, United States",
